Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can this new drug safely reverse a blood thinner? early trial underway

NCT ID NCT07202663

Knowledge-focused Sponsor: Basking Biosciences, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested the safety of a new drug called BB-025, designed to reverse the effects of another experimental drug, BB-031. 72 healthy volunteers received either BB-025 or a placebo, alone or after BB-031, and were monitored for 28 days. The main goal was to check for side effects and measure how the drugs move through the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BB-025 (reversal agent) and BB-031 (RNA aptamer)
What this could lead to
If successful, this could lead to a way to quickly reverse the effects of BB-031, which might be used as a blood thinner.
What could go wrong
This is an early Phase 1 trial in healthy volunteers, not patients. It only tests safety and drug levels, not whether the reversal agent works in a real medical emergency.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

72 people

The number who actually took part.

Started

Nov 2025

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18-55 years of age * Ability to provide written consent * Weight 50-100 kg with BMI 18-32 kg/m2 * Willingness to use contraceptives * Negative results for alcohol and drugs of abuse Exclusion Criteria: * Pregnant or lactating females * Familial bleeding disorder or individual or family history of bleeding diathesis or coagulopathy * Females with active menstruation on day of dosing * Use of prescription medications known to affect platelet function * Use of NSAIDs, aspirin, anti-platelet or anti-coagulation therapy within 10 days of dosing * Contraindication to anticoagulation or increased bleeding risks * History of thrombocytosis, high platelet count, intracranial bleeding, aneurysm, stroke, vascular disease * History of peptic ulcer disease, gastrointestinal or genitourinary bleed, severe trauma, fracture, major surgery of biopsy of parenchymal organ within past 3 months * Planned surgery during the study * Any clinically significant abnormality at screening * Use of investigational drug in past 30 days or 5 half lives * Concurrent enrollment in another clinical study or more than 4 clinical studies in past 12 months * Any prior history of substance abuse or treatment or positive urine screen for drugs of abuse or positive breathalyzer test

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ischemic Stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy volunteers Pharmacodynamics Pharmacokinetics

Contacts and locations

Locations

  • Scintia Clinical Research Ltd

    Randwick, New South Wales, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.